Summary
The treatment of hypertension by costly new drugs such as the angiotensin converting enzyme inhibitors, means that careful monitoring of health care expenditure is essential. If drugs like simvastatin come to be widely used, costs will mount even more. New drugs cannot be used indiscriminately.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Australian National Blood Pressure Study Management Committee. The Australian Therapeutic Trial in Mild Hypertension.Lancet 1980; 1:1261–1267.
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results.Br Med J 1985; 291:97–104.
Louis WJ, Howes LG, Krum H, McNeil JJ. Metabolic risk factors and hypertension.JAMA 1988; 00:13–16.
Louis WJ. Conflict over drug policy in Australia: The need for change.Br Med J 1989; 298:472–473.
Louis WJ, Howes LG, Straznicki N, Krum H, Phillips P, Broadbear J, McNeil JJ. The role of metabolic risk factors in cardiovascular prognosis in hypertension.Am J Cardiol 1989, in press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Louis, W.J. The cost of new drugs in the treatment of hypertension — The Australian experience. Cardiovasc Drug Ther 3, 825–827 (1989). https://doi.org/10.1007/BF01869566
Issue Date:
DOI: https://doi.org/10.1007/BF01869566